SEC FORM 4

Please wait

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILLENNIUM MANAGEMENT LLC

(Last)

(First)

(Middle)

399 PARK AVENUE

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/31/2026		P		616	A	$24.6857⁽¹⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		P		1,770	A	$25.3209⁽⁴⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		P		1,048	A	$26.7259⁽⁵⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		P		17	A	$27.7838⁽⁶⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		P		186	A	$30.4754⁽⁷⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		P		1,957	A	$31.4512⁽⁸⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		P		411	A	$32.5962⁽⁹⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		S		191	D	$24.2843⁽¹⁰⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		S		1,251	D	$25.1676⁽¹¹⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		S		57	D	$27.1147⁽¹²⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		S		5	D	$28.405⁽¹³⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	03/31/2026		S		87	D	$31.52⁽¹⁴⁾	146,657⁽²⁾	I	See footnote⁽³⁾
Common Stock	04/01/2026		P		1,161	A	$31.5309⁽¹⁵⁾	147,731⁽²⁾	I	See footnote⁽³⁾
Common Stock	04/01/2026		P		1,613	A	$34.5863⁽¹⁶⁾	147,731⁽²⁾	I	See footnote⁽³⁾
Common Stock	04/01/2026		P		3,401	A	$35.4554⁽¹⁷⁾	147,731⁽²⁾	I	See footnote⁽³⁾
Common Stock	04/01/2026		S		1,104	D	$31.52⁽¹⁸⁾	147,731⁽²⁾	I	See footnote⁽³⁾
Common Stock	04/01/2026		S		46	D	$34.7464⁽¹⁹⁾	147,731⁽²⁾	I	See footnote⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person^*

MILLENNIUM MANAGEMENT LLC

(Last)

(First)

(Middle)

399 PARK AVENUE

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ICS OPPORTUNITIES II LLC

(Last)

(First)

(Middle)

C/O MILLENNIUM MANAGEMENT LLC

399 PARK AVENUE

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

MILLENNIUM GROUP MANAGEMENT LLC

(Last)

(First)

(Middle)

399 PARK AVENUE

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ENGLANDER ISRAEL A

(Last)

(First)

(Middle)

C/O MILLENNIUM MANAGEMENT LLC

399 PARK AVENUE

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Represents volume-weighted average price ("VWAP") of purchases of 616 shares of common stock ("Common Stock"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the "Company") on March 31, 2026 at prices ranging from $23.91 to $24.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein.

2. In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2.

3. The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any.

4. Represents VWAP of purchases of 1,770 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $25.13 to $26.12.

5. Represents VWAP of purchases of 1,048 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $26.2587 to $27.1994.

6. Represents VWAP of purchases of 17 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $27.525 to $28.405.

7. Represents VWAP of purchases of 186 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $30.1693 to $30.73.

8. Represents VWAP of purchases of 1,957 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $31.215 to $31.17.

9. Represents VWAP of purchases of 411 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $32.4343 to $32.91.

10. Represents VWAP of sales of 191 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $23.91 to $24.6089.

11. Represents VWAP of sales of 1,251 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $25.13 to $25.45.

12. Represents sales of 57 shares of the Company's Common Stock on March 31, 2026 at $27.1147 per share.

13. Represents sales of 5 shares of the Company's Common Stock on March 31, 2026 at $28.4050 per share.

14. Represents sales of 87 shares of the Company's Common Stock on March 31, 2026 at $31.52 per share.

15. Represents VWAP of purchases of 1,161 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $31.52 to $32.50.

16. Represents VWAP of purchases of 1,613 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $34.04 to $34.98.

17. Represents VWAP of purchases of 3,401 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $35.06 to $35.90.

18. Represents sales of 1,104 shares of the Company's Common Stock on April 1, 2026 at $31.52 per share.

19. Represents VWAP of sales of 46 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $34.5271 to $35.3850.

Remarks:

Assuming, without conceding, the application of Section 16(b) of the Securities Exchange Act of 1934, the reporting persons have disgorged to the Company all amounts that could be deemed profit realized by them from the transactions in the Company's Common Stock reported on this Form 4 and the other two statements on Form 4 filed by Millennium Management LLC on the same date.

	MILLENNIUM MANAGEMENT LLC: By: /s/ Gil Raviv, Global General Counsel	05/14/2026
	ICS OPPORTUNITIES II LLC, By: Millennium Management LLC, its Investment Manager: By: /s/ Gil Raviv, Global General Counsel	05/14/2026
	MILLENNIUM GROUP MANAGEMENT LLC: By: /s/ Gil Raviv, Global General Counsel	05/14/2026
	/s/ Israel A. Englander	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.